This is a preview of subscription content, log in via an institution to check access.
Notes
Also see Reactions 1740 p6; 803375340
References
European Medicines Agency. First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban. Internet Document : 1 Mar 2019. Available from: URL: https://www.ema.europa.eu/en/news/first-antidote-reversal-anticoagulation-factor-xa-inhibitors-apixaban-rivaroxaban
Portola Pharmaceuticals Inc. European CHMP Adopts Positive Opinion on Ondexxya(TM) (andexanet alfa) Portola Pharmaceuticals Factor Xa Inhibitor Reversal Agent. Internet Document : 1 Mar 2019. Available from: URL: https://www.globenewswire.com/news-release/2019/03/01/1745215/0/en/European-CHMP-Adopts-Positive-Opinion-on-Ondexxya-andexanet-alfa-Portola-Pharmaceuticals-Factor-Xa-Inhibitor-Reversal-Agent.html
Rights and permissions
About this article
Cite this article
EMA adopts positive opinion for andexanet alfa. Reactions Weekly 1744, 3 (2019). https://doi.org/10.1007/s40278-019-58902-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-58902-4